Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease
Yong-Hee Rhee, … , Kwang-Soo Kim, Sang-Hun Lee
Yong-Hee Rhee, … , Kwang-Soo Kim, Sang-Hun Lee
Published May 16, 2011
Citation Information: J Clin Invest. 2011;121(6):2326-2335. https://doi.org/10.1172/JCI45794.
View: Text | PDF
Research Article

Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease

  • Text
  • PDF
Abstract

Parkinson disease (PD) involves the selective loss of midbrain dopamine (mDA) neurons and is a possible target disease for stem cell–based therapy. Human induced pluripotent stem cells (hiPSCs) are a potentially unlimited source of patient-specific cells for transplantation. However, it is critical to evaluate the safety of hiPSCs generated by different reprogramming methods. Here, we compared multiple hiPSC lines derived by virus- and protein-based reprogramming to human ES cells (hESCs). Neuronal precursor cells (NPCs) and dopamine (DA) neurons delivered from lentivirus-based hiPSCs exhibited residual expression of exogenous reprogramming genes, but those cells derived from retrovirus- and protein-based hiPSCs did not. Furthermore, NPCs derived from virus-based hiPSCs exhibited early senescence and apoptotic cell death during passaging, which was preceded by abrupt induction of p53. In contrast, NPCs derived from hESCs and protein-based hiPSCs were highly expandable without senescence. DA neurons derived from protein-based hiPSCs exhibited gene expression, physiological, and electrophysiological properties similar to those of mDA neurons. Transplantation of these cells into rats with striatal lesions, a model of PD, significantly rescued motor deficits. These data support the clinical potential of protein-based hiPSCs for personalized cell therapy of PD.

Authors

Yong-Hee Rhee, Ji-Yun Ko, Mi-Yoon Chang, Sang-Hoon Yi, Dohoon Kim, Chun-Hyung Kim, Jae-Won Shim, A-Young Jo, Byung-Woo Kim, Hyunsu Lee, Suk-Ho Lee, Wonhee Suh, Chang-Hwan Park, Hyun-Chul Koh, Yong-Sung Lee, Robert Lanza, Kwang-Soo Kim, Sang-Hun Lee

×

Figure 2

Residual expression of reprogramming genes in differentiated cells from hiPSCs.

Options: View larger image (or click on image) Download as PowerPoint
Residual expression of reprogramming genes in differentiated cells from ...
(A) Oct4 expression in hiPSC-NPCs. Substantial Oct4 expression was detected in NPCs derived from all 4 lentivirus-based hiPSCs. (B) Oct4 expression was also detected in nestin+ NPCs and in TuJ1+ and TH+ neurons from lentivirus-based hiPSCs before (left) and after (middle and right) terminal differentiation for 7 days. Scale bars: 30 μm. Boxed regions are shown enlarged in the insets (×3). (C) Upregulation of Oct4 expression by cAMP treatment. Lenti-3 NPCs were induced to differentiate by withdrawal of bFGF in the absence (No treat) or presence of BDNF, GDNF, or cAMP for 7 days. The percentage of Oct4-positive cells was counted (n = 4 coverslips per group). *P < 0.01 vs. untreated control, ANOVA with Tukey post-hoc analysis. (D) RT-PCR expression analyses for exogenous and endogenous genes. The indicated hiPSCs were cocultured and sequentially differentiated as in Figure 1A. RNAs were prepared from each step: undifferentiated, coculture with MS5, MS5-SHH, NPCs, and differentiated neurons (DA). Primers specific for exogenous (exo; proviral) and endogenous (endo; chromosomal) expression were used. GDF3, REX1, and DNMT3L were used as undifferentiated markers. N/D, not determined; N/A, not applicable (NANOG was not used for establishing the retrovirus-based iPSCs).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts